Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial. (linkinghub.elsevier.com)

Authors: Ager CR … Dallos MC Journal: Cell Reports Medicine Published: 2026-03-17 DOI: https://doi.org/10.1016/j.xcrm.2026.102638